|
Tuesday, March 25 — 8:00 AM — Cotillion North
Click on the numbers in parentheses to display abstracts.
Section D - BREAST PATHOLOGY
Chaired by: Ira Bleiweiss and James Connolly
| 8:00 |
Amount of Invasive and In-Situ Carcinoma near the Margin Is the Key Factor Associated with Ipsilateral Breast Failure in Patients with Invasive Breast Carcinoma Treated with Breast Conserving Therapy
(120)
NS Goldstein, L Kestin, F Vicini
William Beaumont Hospital, Royal Oak, MI
|
| 8:15 |
A New Method of Complete Peripheral Margin Assessment in Breast Conservetive Surgery To Detect Positive Sites Nonrecognizable by Conventional Inked Margin Method: Polygon System
(137)
S Ichihara, Y Mori, T Yokoi, Y Yatabe, S Nakamura, H Suzuki, K Iwata
Nagoya National Hospital, Nagoya, Aichi, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan
|
| 8:30 |
Lack of Predictive Value for Counting Foci of Atypical Ductal Hyperplasia in Breast Needle Core Biopsies
(107)
RR Dalton, DB Sullivan, PG Klacsmann
Medical College of Georgia, Augusta, GA; University Hospital, Augusta, GA
|
| 8:45 |
Biology of Columnar Cell Lesions in Core Biopsies of Breast
(105)
DJ Dabbs, RL Kessinger, K McManus, R Johnson
Magee-Womens Hospital, Pittsburgh, PA
|
| 9:00 |
Pathologic Features of Breast Cancer Associated with Complete Response to Neoadjuvant Chemotherapy: Importance of Histologic Type and Grade
(207)
DE Sturtz, AF Schott, CG Kleer
University of Michigan, Ann Arbor, MI
|
| 9:15 |
Topoisomerase IIa Expression and Response to Anthracycline-Based Neoadjuvant Chemotherapy: Results from a Randomized Clinical Trial
(195)
R Schwartz, S Schnitt, A Rousseau, V Dieras, J Couturier, P de Cremoux, N Pliss, X Sastre-Garau, A Vincent-Salomon
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Institut Curie, Paris, France
|
| 9:30 |
RECESS, EXHIBITS, POSTER SESSION III
|
| 11:00 |
The Use of Predicting Factors and Surrogate Markers in Breast Cancer Biopsies Treated with Targeted erbB Tyrosine Kinase Inhibitor
(88)
SS Bacus, P Beresford, Y Yarden, N Spector
Quantitative Diagnostics Laboratory, Inc., Westmont, IL; Weizmann Institute of Science, Rehovot, Israel; GlaxoWellcome, Research Triangle Park, NC
|
| 11:15 |
Insulin-Like Growth Factor-I Receptor (IGF-IR) Expression in HER2-Overexpressing Breast Cancers: Frequency, Patterns and Implications for Herceptin Resistance
(218)
AK Witkiewicz, N Pliss, SJ Schnitt
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
|
| 11:30 |
Do Morphologically Similar Areas That Stain Differently by Immunohistochemistry Correlate with Differences in Gene Amplification? The Reliability of Tissue Array in the Assessment of HER-2/NEU (H2N) Gene Amplification in Archival Breast Carcinoma Samples
(203)
SJ Shin, E Hyjek, E Early, DM Knowles
Weill Medical College of Cornell University, New York, NY
|
| 11:45 |
In-Situ Hybridization for Beta4 Integrin Subunit in Node-Negative Invasive Carcinoma of the Breast
(110)
LK Diaz, M Cristofanilli, X Zhou, K Welch, TL Smith, N Sneige, A Sahin, MZ Gilcrease
M. D. Anderson Cancer Center, Houston, TX
|
|
|
